This article was updated by an external expert under a dual publication model. The corresponding peer-reviewed article was published in for the journal Open Medicine. Click to view.

Biology:TRPV6

From HandWiki
Short description: Protein-coding gene in the species Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

TRPV6 is a membrane calcium (Ca2+) channel protein which is particularly involved in the first step in Ca2+absorption in the intestine.

Classification

Transient Receptor Potential Vanilloid subfamily member 6 (TRPV6) is an epithelial Ca2+ channel that belongs to the transient receptor potential family (TRP) of proteins.[1] The TRP family is a group of channel proteins critical for ionic homeostasis and the perception of various physical and chemical stimuli. TRP channels can detect temperature, osmotic pressure, olfaction, taste, and mechanical forces.[1][2] The human genome encodes for 28 TRP channels, which include six TRPV channels.[1] The high Ca2+-selectivity of TRPV5 and TRPV6 makes these channels distinct from the other four TRPV channels (TRPV1-TRPV4).[3] TRPV5 and TRPV6 are involved in Ca2+ transport, whereas TRPV1 through TRPV3 are heat sensors with different temperature threshold for activation, and TRPV4 is involved in sensing osmolarity.[4][5] Genetic defects in TRPV6 gene are linked to transient neonatal hyperparathyroidism and early-onset chronic pancreatitis. Dysregulation of TRPV6 is also involved in hypercalciuria, kidney stone formation, bone disorders, defects in keratinocyte differentiation, skeletal deformities, osteoarthritis, male sterility, Pendred syndrome, and certain sub-types of Cancer.[4][5]

Identification

Peng et al identified TRPV6 in 1999 from rat duodenum in an effort to search for Ca2+ transporting proteins involved in Ca2+absorption.[6] TRPV6 was also called calcium transport protein 1 (CaT1)[6][7] initially although the names epithelial calcium channel 2 (ECaC2)[8][9] and CaT1-like (CaT-L)[10] were also used in early studies to describe the channel.[6][8][9][10] The human and mouse orthologs of TRPV6 were cloned by Peng et al and Weber et al, respectively.[7][8] The name TRPV6 was confirmed in 2005.[11]

Gene location, chromosomal location, and phylogeny

The human TRPV6 gene is located on chromosomal locus 7q33-34 close to its homolog TRPV5 on 7q35.[12][13] The TRPV6 gene in human encodes for 2906 bp-long mRNA.[13] In contrast to most other proteins, which initiate translation with an AUG codon, TRPV6 translation is initiated by non-AUG-codon-mediated reading.[14] TRPV6 protein bears a 40-a.a-long N-terminal extension in placenta and in some physiological settings in comparison to the annotated version of the protein used in biological studies.[14] However, it is still to be determined whether the long version of the TRPV6 protein is the dominant form in different tissues.

Chromosomal location and identifiers
Species Human Rat Mouse
Chromosomal location 7q33-q34 4q22 6B2
Annotated aa length 725 727 727
In vivo aa lengtha 765 767 767
RefSeq nucleotide NM_018646 NM_053686 NM_022413
RefSeq protein NP_061116 NP_446138 NP_071858

aTo be verified in different tissues.

It has been hypothesized that Trpv5 and Trpv6 genes were generated from a single ancestral gene by gene duplication events.[12][15] Phylogenetic analysis has shown that TRPV6 paralogs in mammals, sauropsids, amphibians, and chondrichthyes arose out of independent duplication events in the ancestor of each group.[15] It is speculated that two specialized Ca2+-selective Trpv homologs arose as an adaptation to achieve a greater degree of functional specialization for navigating distinct renal challenges of terrestrial animals.[15]

Two alleles of the TRPV6 gene have been identified in humans (originally noted as CaT-La and CaT-Lb).[10] These alleles exhibit coupled polymorphisms generating two versions of the same gene.[10][16] The polymorphisms give rise to an “ancestral variant” and a “derived variant” that differ in five bases and three amino acids.[10][16] The ancestral allele codes for C197(157, in parentheses are annotated amino acid numbering), M418(378), and M721(681) whereas the derived allele codes for R197(157), V418 (378) and T721(681).[16][17] The frequency of the ancestral TRPV6 allele varies across different population groups.[16][17] It is hypothesized that selection pressures that could have changed TRPV6 allele distribution include changes in patterns of milk consumption, domestication of animals, change in ultraviolet light exposure due to trans-equatorial migration, genomic adaptations providing immune advantages to populations encountering new pathogens.[16][17][18]

Tissue distribution

The TRPV6 protein is expressed in epithelial tissues such as the intestine, kidney, placenta, epididymis, and exocrine glands such as pancreas, prostate and salivary, sweat, and mammary glands.[19][20] TRPV6 protein expression in humans has been demonstrated in the esophagus, stomach, small intestine, colon, pancreas, mammary glands, ovary, thyroid, and prostate by immunohistochemistry approaches.[19] TRPV6 expression mainly confines on the apical membrane of epithelial cells. In the intestine, the protein is expressed on the brush-border membrane of enterocyte.

Differences in the TRPV6 expression profile have been reported possibly due to variation in assay-dependent such primer design, hybridization probes, PCR vs. northern blotting, semi-quantitative PCR vs. RT-PCR, and antibodies used for immunodetection.[21] TRPV6 expression profile is also influenced by age, gender, Ca2+ and vitamin D3 levels in food, hormonal status, location within the tissue, cellular location, reproductive status, and weaning status (see Section Regulation).

In humans, TRPV6 transcripts have been detected in the placenta, pancreas, prostate cancer, and duodenum and the prostate by northern blotting; and in duodenum, jejunum, placenta, pancreas, testis, kidney, brain, and colon by semi-quantitative PCR.[9] In rodents, TRPV6 expression has been validated in the duodenum, cecum, small intestine, colon, placenta, pancreas, prostate, and epididymis by Northern Blotting.[6][13][22] In mouse, TRPV6 transcript abundance measured by RT-PCR is as follows: prostate > stomach, brain > lung > duodenum, cecum, heart, kidney, bone > colon > skeletal muscle > pancreas.[23]

Data from Human Protein Atlas and RNA-Seq based suggest TRPV6 mRNA is low in most tissues except for the placenta, salivary gland, pancreas, and prostate.[20][24] TRPV6 mRNA is expressed in the apical domain of murine osteoclasts of cortical bone.[25][26] Cortical and trabecular osteocytes do not express TRPV6 mRNA whereas osteoblasts show weak expression.[27]

Structure and biophysical properties

Primary and secondary structure

Figure 1. Domain organization of TRPV6. TRPV6 monomer contains the following structure elements: an N-terminal helix, an ankyrin repeat domain with six ankyrin repeats (ANK1-6), a linker domain composed of a β-hairpin (β1 and β2) and two linker helices (LH1 and LH2), a pre-S1 helix connecting the linker domain, and the transmembrane (TM) domain that comprises six TM helices (S1-S6) and a pore helix connecting S5 and S6, an amphipathic TRP helix, a β-strand forms a β-sheet with β1 and β2, and two C-terminal interacting helices (CIH1 and CIH2). The orientation of the domains is based on that of a cryo-electron microscopy structure of human TRPV6 (PBD: 6E2F). The positions of the glycosylation site, the key selective residue in the selective filter, a representative residue in the lower gate are also labeled.

Overall, four subunits of TRPV6 arrange to form a tetrameric channel displaying a four-fold symmetry.[4][28] Beginning from N-terminus and moving towards the C-terminus of the protein, each TRPV6 polypeptide contains: an N-terminal helix, an ankyrin repeat domain (ARD) containing six ankyrin repeats, a β-hairpin structure linker domain made up two β-strands, a helix-turn-helix motif, a pre-SI helix, TM domain made up of six TM helices (S1 through S6), a pore-loop (also called P-loop), amphipathic TRP helix, C-terminal hook, and a six-residue β-strand (β3) (Figure 1).[4][28]

Tertiary and quaternary structure

Figure 2. A cryo-electron microscopy structure of human TRPV6 tetramer. Four subunits of TRPV6 arrange to form a four-fold symmetric channel. Shown are cryo-electron microscopy structures of human TRPV6 in open state (PBD: 6BO8). Each subunit is shown in a unique color.

The TRPV6 channel protein displays four-fold symmetry and contains two main compartments: a 30 Å-tall transmembrane domain with a central ion channel pore and a ~70 Å-tall and a ~110 Å-wide intracellular skirt enclosing a 50 Å × 50 Å cavity wide cavity underneath the ion channel.[28] The clustering of four TRPV6 subunits forms an aqueous pore exhibiting a fourfold symmetry (Figure 2). A pre-SI helix links the intracellular portion of the protein to the TM domain through a linker domain made up of β-hairpin structure and a helix-turn-helix motif. Helices S1 through S4 form a transmembrane helical bundle or TM domain that is inserted almost perpendicularly to the plane of the plasma membrane.[28]

The pore module elements are made up of S5, S6, and the P-loop in TM domains.[28] The pore module from each TRPV6 polypeptide participates in inter-subunit interactions to form a central ion pore (Figure 1).[28] The pore-forming elements of each TRPV6 subunit also interact with S1-S4 domains of the adjacent polypeptide in a domain-swapped arrangement.[28][29] Intersubunit interactions also occur between S1-S2 extracellular loops and S5-P and S6-P loops of the neighboring TRPV6 subunits.[28] The conserved N-linked glycosylation site on the S1-S2 loop is required for by the Klotho-mediated activation.[30] The intracellular skirt portion of the TRPV6 protein is mainly made up of the ankyrin repeats.[28] The TRP domain is oriented parallel to the membrane and participates in hydrophobic interactions with the TM domain and the hydrophilic interactions in the intracellular skirt. The N-terminal helix, C-terminal hook, and β-sheets (formed by the β-hairpin structure in the linker domain) in the channel participates in intersubunit interactions with the ARDs to provides a framework for holding the elements of the intracellular skirt together.[4][28]

Pore architecture and cation binding sites

The TRPV6 pore has four main elements, namely, the extracellular vestibule, a selectivity filter, a hydrophobic cavity, and a lower gate.[28][31][32] Facing the central lumen of the channel, a four-residue selectivity filter (538TIID541) containing four Aspartate 541 (D541) side chains (one from each protomer) is critical for Ca2+ selectivity and other biophysical properties of the channel.[28][31][32] This filter forms a negatively charged ring that discriminates between ions based on their size and charge. Mutations in the critical pore-forming residue of TRPV6 blocks Ca2+uptake, a strategy has been used to generate TRPV6 loss-of-function models to examine the role of the channel in animal physiology.[31][32] Four different types of cation binding sites are thought to exist in the TRPV6 channel.[28] Site 1 is located in the central pore and shares the same plane that is occupied by the key selective residues D541. Site 2 is thought to be present about 6-8 Å below Site 1 followed by Site 3 which is located in the central pore axis about 6.8 Å below Site 2. Site 2 and 3 are thought to interact with partially-hydrated to equatorially-hydrated Ca2+ ions. Finally, four symmetrical cation binding sites in the extracellular vestibule mediate the recruitment of cations towards the extracellular vestibule of TRPV6 and are referred to as recruitment sites.[28]

Ion permeation

The conductance of TRPV6 for divalent cations follows the preference: Ca2+ > Ba2+ > Sr2+ > Mn2. Intra-cellular Mg2+ inhibits TRPV6 and contributes to the strong inward rectification exhibited by the channel.[33] TRPV6 uptake activity is inhibited by divalent Pb2, Cu2+, Cd2+, Zn2, Co2+, Fe2+, and trivalent cations La3+, Fe3+, Gd3+. The concentration of ions to achieve the inhibition ranges from 1 to 10 μM.[34] The TRPV6 protein is constitutive with a single-channel conductance of 42-58 ps.[3][35] At low Ca2+ concentrations, a single Ca2+ ion binds in the selectivity filter formed by D541 and permits Na+ permeation. At high Ca2+ concentration, Ca2+ permeation occurs by a knock-off mechanism that involves the formation of short-lived conformations involving binding of three Ca2+ ions to residue D541.[35]

Channel gating

Figure 3. Gating mechanism of TRPV6. Shown are the closed and open conformations of the S6 transmembrane domain of TRPV6. The opening of the lower gate is caused by an α- to the π-helical transition of the transmembrane helix S6 at residue A566, which induces the intracellular part of S6 bends by about 11º and rotates by about 100º. This ensures that the conformation of the selectivity filter is not significantly altered and the ionic selectivity is maintained.

The conformational changes involved in channel opening are hinged around the residue Alanine 566 (A566) and occur in the pore-lining helix S6 (Figure 3).[35] The upper portion of S6 helix undergoes an α-to-π helical transition which forces the lower portion of the helix to turn by 100 degrees and tilt away from the pore axis by 11 degrees.[35] This conformational change moves the lower portion of the helix gating the pore and thereby widens the pore size. The conformational change alters the residues facing the pore axis and triggers the formation of new electrostatic bonds subunit and salt bridges that offset the high energetic cost of unfavorable α-to-π helical transition that occurs during channel opening.[35]

Regulation by phosphatidylinositol 4,5-bisphosphate (PIP2) and calmodulin (CaM)

The influx of Ca2+ inside the cell triggers negative feedback mechanisms to suppress TRPV6 activity and prevent Ca2+ overload.[5] TRPV6 channel activity is regulated by the intracellular level of phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) and interactions with Ca2+-Calmodulin (CaM) complex.[5] The depletion of PIP2 or CaM-binding inactivates TRPV6.[36][37][38][39][40] The influx of Ca2+ in TRPV6 expressing cells activates phospholipase C (PLC) which in turn hydrolyzes PIP2. Depletion in PIP2 levels results in a decline in channel activity since most TRP channels require this lipid for activation.[36][39][40] The lipid PIP2 can override Ca2+-CaM-mediated inhibition of TRPV6. Overall, TRPV6 inactivation by calmodulin is orchestrated by a balance of intracellular Ca2+ and PIP2 concentration.[36][37][38][39][40]

Interacting proteins

Among 20+ TRPV6 interactors identified so far, the functional consequences of Ca2+-binding protein Calmodulin (CaM) and Glucuronidase Klotho have been most extensively characterized [36, 37, 41, 42].[30][36][37][41][42] Functional consequences of TRPV6 channel activation are summarized in the table below).[43]

TRPV6 Interactors and their Functional Consequences
Interactor Consequence
BSPRY N/A
Calbindin-D28k N/A
Calmodulin Inhibition
Cyclophilin B Activation
FYN PO4lyation
I-MFA N/A
Klotho Activation, Glycosylation (Asn-357)
NHERF4 Activation
NIPSNAP1 Inhibition
NUMB Inhibition
PTEN N/A
PTP1B DePO4lyation

(Tyr-161 and Tyr-162)

RAB11A Activation,

Increase in Plasma membrane level

RGS2 N/A
RYR1 N/A
S100A10 Activation,

Increase in Plasma membrane level

SRC PO4lyation (Tyr-161, 162)
TRPC1 Retains in ER, Inhibition
TRPML3 N/A
TRPV5 Tetramer formation,

New Channel creation

Abbreviations

Protein Interactor

BSPRY: B-Box and Spry Domain Containing Protein; FYN: Fyn Kinase Belonging Src Family of Kinases; I-MFA: Myo D Family Inhibitor; NHERF: Na Exchanger Regulatory Factor; NIPSNAP14-Nitrophenylphosphatase Domain and Non-Neuronal SNAP25-Like Protein Homolog 1; Numb: Drosophila mutation that removes most of the sensory neurons in the developing peripheral nervous system; PTP: Protein Tyrosine Phosphatase; Rab11a: Member RAS Oncogene Family; RGS2: Regulator Of G-Protein Signaling 2; RyR1: Ryanodine Receptor 1; TRPC1: Transient receptor potential canonical 1; TRPML3: Transient receptor potential Mucolipin-3.

Physiological functions

The Ca2+-selective channel proteins TRPV6 and TRPV5 cooperate to maintain calcium concentration in specific organs.[18][44] TRPV6 functions as apical Ca2+ entry channels mediating transcellular transport of this ion in the intestine, placenta, and possibly some other exocrine organs. TRPV6 also plays important roles in maternal-fetal calcium transport,[45] keratinocyte differentiation,[46] and Ca2+ homeostasis in the endolymphatic system of the vestibular system,[47][48] and maintenance of male fertility.[49][50]

Ca2+ absorption in intestine

Figure 4. Role of TRPV6 in intestinal calcium absorption. TRPV6 mediates Ca2+ entry across the plasma membrane as the first step in the transcellular pathway of Ca2+ transport. This is considered the rate-limiting step in Ca2+ absorption by the enterocytes. The transcellular pathway enables the transport of Ca2+ against a [Ca2+] gradient to ensure Ca2+ absorption when the luminal [Ca2+] is lower than that in the blood side; The Ca2+ binding protein calbindin-D9k and plasma membrane Ca2+ ATPase (PMCA) are known components in these transcellular pathways.

Two routes of Ca2+ absorption are recognized: paracellular transport and transcellular transport (see Figure 4).[51] A high-Ca2+-diet favors paracellular transport of the ion across the length of the intestine allowing them to pass between the intercellular tight junctions that connect epithelial cells. In contrast under conditions when [Ca2+] in the lumen of the intestine is lower in comparison to its concentration in the plasma (e.g. during low dietary Ca2+), the transcellular pathway is required for adequate Ca2+ absorption. Three important steps in transcellular Ca2+ transport are recognized: cellular entry of Ca2+ ion on the apical side via TRPV6 (Step-1), the binding of Ca2+ ion with calbindin-D9k (Step-2), and exit of Ca2+ from the basolateral side via the plasma membrane Ca2+ ATPase (PMCA1b).[51] The hormone Vitamin D3 (or 1,25(OH)2D3) plays an important role in TRPV6-mediated intestinal Ca2+ absorption).[51]

Ca2+ reabsorption in the kidney

In contrast to the intestine, where TRPV6 is the gatekeeper of Ca2+ absorption, the transcellular reabsorption of this ion in the kidney occurs through TRPV5. Although TRPV5 is a recognized gatekeeper for transcellular reabsorption of Ca2+ ion in the kidney, TRPV6 knockout (KO) mice also struggle to concentrate their urine and display hypercalciuria.[52] TRPV6 is known to co-localize with TRPV5 Calbindin-D28K in apical domains of distal convoluted tubules and connecting tubules [20]. TRPV5 KO mice compensate for Ca2+ loss by increasing TRPV6 expression in the duodenum.[52] Moreover, a recent study analyzing vitamin D responsive genes in ovine, canine and, equine kidney suggested that TRPV6, calD9k/calD28k, and PMCA could be the main pathways orchestrating transcellular Ca2+ transport in the kidney of sheep, dogs, and horses.[53]

Maternal-fetal Ca2+ transport

TRPV6 plays an indispensable role in placental Ca2+ transport.[45] Fetal bone mineralization peaks during late pregnancy. At this stage, fetal blood has a higher concentration of Ca2+ in comparison to maternal blood thereby creating conditions that require active transcellular transport of Ca2+ from mother to the fetus.[54][55] This process is very important since defects in placental transport of calcium can be precursors for Ca2+ deficiency syndromes and intrauterine growth restrictions.[56] The expression of TRPV6 increases 14-fold during the last 4 days of the murine gestational period and coincides with the peak phase of fetal bone mineralization.[45] The protein TRPV6 is abundantly expressed in the mammalian placental tissues.[45][57][58][59][60] Indeed, TRPV6 expression is ~1000-fold higher in comparison to TRPV5. In the placenta, TRPV6 is expressed in trophoblasts and syncytiotrophoblasts.[10][57] In mice, TRPV6 mRNA and protein are expressed in the intraplacental yolk sac and the visceral layer of the extraplacental yolk sac.[45] Most importantly, TRPV6 KO fetuses exhibit a 40% reduction in 45Ca2+ transport activity and a dramatic decrease in the ash weight (a measure of fetal bone health).[45] In humans, trophoblasts fluid shear stress (FSS) is known to induce a TRPV6-mediated Ca2+ influx and promote microvilli formation through a mechanism involving Ezrin and Akt-phosphorylation.[61]

Epididymal Ca2+ regulation and implications on male fertility

The regulation of calcium concentration in the epididymal lumen is critical for sperm motility.[62] TRPV6-mediated reduction of luminal Ca2+ concentration in the epididymis is critical for male fertility in mice.[49] TRPV6 KO mice or mice expressing loss-of-function version of TRPV6 channel (Trpv6D541A homozygous mice) have a severely impaired fertility.[49] Mice expressing nonfunctional TRPV6 have a 10-fold higher concentration of Ca2+ in the epididymal lumen and Ca2+ uptake in this space is reduced by 7-to-8 folds.[49][50] The increases Ca2+ ion in epididymal lumen concentration leads to significant defects in motility, fertilization capacity, and viability of sperms in TRPV6D541A mice.[49][50] It appears TRPV6 and chloride channel transmembrane manner 16 A (TMEM16A) act cooperatively to reduce the luminal concentration of Ca2+ in the epididymal lumen.[63]

Bone health

Under conditions of sub-optimal dietary Ca2+, normal serum calcium levels in TRPV6 KO mice are maintained at the expense of bone.[64][65] TRPV6 plays an important role in osteoclasts but not in osteoblasts.[64][65] In mice, TRPV6 depletion results in increased osteoclasts differentiation[25] whereas TRPV5 is essential for proper osteoclastic bone resorption.[64]

Keratinocyte differentiation

Keratinocytes differentiation is orchestrated by calcium switch, a process that entails an influx of Ca2+ in keratinocyte which induces broad transcriptional changes necessary for desmosome formation, stratification, and cornification.[66] TRPV6 KO mice display thinner layers of stratum corneum and 20% of the mice also show alopecia and dermatitis.[52] The silencing of TRPV6 impairs Ca2+-mediated differentiation of human primary keratinocytes and downregulates differentiation markers such as involucrin, transglutaminase-1, and cytokeratin-10. The hormone 1,25-dihydroxyvitamin-D3 upregulates TRPV6 in keratinocytes and triggers a Ca2+ influx. This in turn induces the expression of keratinocyte differentiation-specific pathways.[46]

Role in the inner ear

The proteins TRPV5 and TRPV6 are expressed in several regions of the inner ear as well as in primary cultures of semicircular canal duct (SCCD) epithelium.[47][48] Some studies have indicated that TRPV5 and TRPV6 are needed for lowering the Ca2+ concentration in the lumen of mammalian endolymph, a requirement that is essential for normal hearing and balance.[47][48][67]

Uterine and placental expression of TRPV6 and implications in pregnancy

The endometrial and uterine expression of TRPV6 has been reported in mammals.[68][69][70] The expression of TRPV6 in the uterus is thought to be hormonally regulated by 17β-estradiol and progesterone in rodents. In rodents, TRPV6 mRNA is expressed in the labyrinth and spongy zone as well as placenta-unattached areas of the uterus. The stage of pregnancy is an important regulator of TRPV6 expression. The downregulation of TRPV5/6 expression and a resulting decline in Ca2+ transport is thought to change the proliferative profile of human trophoblasts; a process which in turn is linked to the development of pre-eclampsia.[69] This juxtaposition of TRPV6 expression and its stringent regulation by sex hormones during pregnancy suggest that the protein may be important for embryo implantation, however conclusive evidence for this connection does not exist.[68][69][70]

Implications in Human Diseases

Transient Neonatal Hyperparathyroidism

Loss of TRPV6 in murine placenta severely impairs Ca2+ transport across trophoblast and reduces embryo growth, induces bone calcification, and impairs bone development. In humans, the insufficient maternal-fetal transport caused by pathogenic genomic variants of TRPV6 is thought to be a cause for skeletal defects observed in selected case reports of transient neonatal hyperparathyroidism (TNHP) cases. These variants are believed to compromise the plasma membrane localization of the protein. Exome sequencing of an infant with severe antenatal onset thoracic insufficiency with accompanying fetal skeletal abnormalities indicates the critical role of TRPV6 in maternal-fetal transport. The study indicated that compound heterozygous variants of TRPV6 result in severe undermineralization and severe dysplasia of the fetal skeleton.[71][72][73]

Chronic Pancreatitis

Recent evidence indicates that naturally occurring TRPV6 loss of function variants predisposes certain demographics to chronic pancreatitis (CP) by dysregulating calcium homeostasis in the pancreatic cells.[74][75] Sequencing studies among chronic pancreatitis patients revealed the presence of 33 missense and 2 nonsense variants predisposed Japanese, German, and French patients to a higher risk of CP.[75] Overall, these studies have shown that disease-inducing TRPV6 loss-of-function genomic variants are over-represented in German, French, Chinese, and Japanese CP patients in comparison to controls in their respective groups.[74][75] The loss-of-function variants are believed to compromise calcium transport in the pancreas by act by either reducing the total protein level and/or compromising Ca2+ uptake activity by the channel.[75]

Kidney Stone Formation

The role of TRPV6 in renal stone formation has been suggested through sequencing studies conducted on a cohort of 170 patients in Switzerland .[76] The studies revealed that the frequency of TRPV6 gain-of-function haplotype is significantly higher in Ca2+-stone formers (nephrolithiasis) in comparison to non-formers. The observed hypercalciuria phenotypes from animal studies and studies on TRPV6 single nucleotide polymorphisms (SNPs) suggest that TRPV6 haplotype could be an important risk factor for absorptive and renal hypercalciuria (kidney stones due to impaired intestinal absorption and renal re-absorption respectively). The lower incidence of kidney stone diseases in African-Americans and a relatively higher prevalence of ancestral haplotype suggest theory according to which this haplotype endows an advantage of increased Ca2+ reabsorption in this demographic and reduces the incidence of kidney stones.[10][16][18][76]

Bone Resorptive Diseases

TRPV6 KO mice exhibit osteoporosis-like symptoms such as reduced bone mineral density and hypercalciuria.[52] The hormone estrogen, the deficiency of which is linked to post-menopausal osteoporosis, also regulates the expression of TRPV6 in humans. Indeed, a lower calcium absorption seen in older postmenopausal women is attributed to reduced TRPV6.[77] The C-terminal portion of Soricidin is a drug that inhibits Ca2+-uptake activity by binding to TRPV6. Preclinical studies of this drug have shown great promise in the treatment of bone resorptive diseases.[24]

The high degree of similarity between Hereditary Vitamin D–Resistant Rickets (HVDRR) disease symptoms and observed phenotypes in TRPV6 KO mice has led some experts to postulate pathological connections between the disease and TRPV6 dysfunction.[44] TRPV6 plays an important chondroprotective role by regulating multiple aspects of chondrocyte function, such as extracellular matrix secretion, the release of matrix-degrading enzymes, cell proliferation, and apoptosis.[78] Furthermore, TRPV6 knockout mice display multiple osteoarthritis (OA) phenotypes such as cartilage fibrillation, eburnation, and loss of proteoglycans.[78]

Pendred Syndrome

The dysfunction gene Slc26a4 has been linked to Pendred syndrome – a genetic disorder that results in syndromic deafness in children.[67][79] The disease is caused by mutations in which compromise the function of the encoded protein pendrin - an anion Cl−/HCO3 − exchanger expressed in the inner ear.[67][79] The loss of function in this gene is thought to reduce the pH value of mammalian endolymph and impair Ca2+ absorption via TRPV5 and TRPV6.[79] This in turn could prevent the uptake of Ca2+ and impairs the luminal reduction in Ca2+ concentration within the endolymphatic system of the ear.[67][79]

Cancer

The overexpression of TRPV6 has been validated in the colon, parathyroid, pancreatic, and thyroid cancer[19] whereas its expression is reportedly downregulated in esophageal cancer,[80] non-small cell lung cancer,[81] and renal cancer.[82] TRPV6 is considered to be an oncochannel that is hypothesized to mediate cancer progression by triggering Ca2+-entry induced aberrations in molecular drivers regulating processes such as cell cycle, apoptosis, and migration; thereby conferring proliferative and survival advantages to cancer cells.[21][24][83] Overexpression of TRPV6 correlates strongly with pathological stage, tumor grade, extra-prostatic invasion, lymph node metastasis, and resistance to androgen-targeted therapies in prostate cancer.[10][19][83][84] The expression TRPV6 has been touted as a prognostic marker for advanced prostate cancer since its expression is strongly dependent on the grade of the tumor.[83][84] Expression of TRPV6 is significantly elevated in breast adenocarcinoma tissue in comparison to normal breast tissue.[85][86] TRPV6 expression has been reported multiple breast cancer cell lines and prostate cancer cell lines.[83][87][88][89] The prostate cancer cell lines PC-3 and LnCAP overexpress TRPV6 relative to benign epithelial cells PrEC and BPH-1.[83] The silencing of TRPV6 in prostate cancer cells decreases proliferation rate, S-phase accumulation, and expression of tumor marker proliferating cell nuclear antigen (PCNA) expression.[88] TRPV6 overexpression is believed to induce aberrant Ca2+-uptake in prostate cancer line and activate transcription factor Nuclear Factor of Activated T cells (NFAT).[88]

Expression of TRPV6 is upregulated by estrogen, progesterone, and estradiol in breast cancer cell line T47D.[86] In agreement with these observations, the estrogen receptor antagonist Tamoxifen reduces TRPV6 expression in T47D cells and suppresses Ca2+-uptake of the channel in both ER-positive and ER-negative breast cancer cell lines.[90] The overexpression of TRPV6 is associated with early-stage colon cancer and its silencing in colon cancer induces apoptosis and inhibits cancer cell proliferation.[91] In terms of mechanism, mutations within the calmodulin-binding domains of TRPV6 channels confers invasive properties to colon adenocarcinoma cells.[92] The proteins p38α and GADD45α are believed to upregulate TRPV6 expression signaling in SW480 colon cancer cells by enhancing vitamin D signaling.[93] TRPV6 has been reported to amplify Insulin-like growth factors (IGF)-induced PI3K-PDK1-Akt signaling in human colon cancer and promote colon cancer.[94]

TRPV6 is up-regulated in primary cancer tissues from pancreatic cancer patients and promotes the proliferation of pancreatic neuroendocrine tumors NFAT-dependent mechanisms.[95] Silencing of TRPV6 induces apoptosis and cell cycle arrest in pancreatic cancer cells and inhibits their invasion, proliferation, and migration.[96] Forced expression of TRPV6 in gastric cancer cells increases their sensitivity to capsaicin-induced apoptosis whereas the siRNA-mediated silencing of the channel suppresses this sensitivity.[97] TRPV6 downregulation in esophageal carcinoma has been suggested to be a prognostic marker of disease-specific survival in patients suffering from esophageal cancer.[98] Low TRPV5 and TRPV6 co-expression have suggested as predictive markers for poor recurrence-free survival in non-small cell lung cancer.[81]

Pharmacological Targeting

Several chemical inhibitors are known to inhibit TRPV6. Some compounds that have demonstrated inhibitory activity towards TRPV6 include TH-1177, 2-Aminoethoxydiphenyl borate (2-APB), 2-APB derivative 22b, Econazole, Miconazole, Piperazine derivative Cis-22a, Capsaicin, Δ9-tetrahydrocannabivarin, Xestospongin C, Lidocaine, gold-caged nanoparticle (PTX-PP@Au NPs) and Sorcidin C-13 (SOR-C13) synthetic peptide.[24] Among different inhibition strategies tested so far, the 13-amino acid peptide SOR-C13 has shown the most promise. This 13-amino acid peptide derived from 54-amino acid peptide found in the paralytic venom of the northern short-tailed shrew (Blarina brevicauda) reduces cancer growth in cell and animal models. This anti-cancer agent has recently completed a Phase I clinical safety trial that had enrolled 23 patients with advanced solid tumors of epithelial origin non-responsive to all standard-of-care treatments.[24]

Regulation

The regulation of TRPV6 can be examined mainly in the context of its physiological, hormonal, and molecular factors.[18] The hormonal regulation of TRPV6 has been characterized most extensively. In this regard, its regulation by the hormone vitamin D3 and sex hormones has been examined in considerable detail. Rodent studies suggest that the TRPV6 channel is regulated by a wide range of physiological factors such as diet, age, gender, pregnancy, lactation, sex hormones, exercise, age, and gender. Some biological and pharmacological agents known to regulate TRPV6 include glucocorticoids, immunosuppressive drugs, and diuretics.[18]

Vitamin D

Multiple dose-response and time-course experiments in rodents and colon cancer cell lines have conclusively shown TRPV6 mRNA is robustly induced by this vitamin D at extremely low concentrations.[99][100] At least five vitamin D response elements (VDREs) at positions −1.2, −2.1, −3.5, −4.3, and −5.5 kb relative to transcriptional start site (TSS) have been identified on TRPV6 transcripts.[101] Among these five sites, VDREs at positions −1.2, −2.1, and −4.3 kb are significantly more responsive to 1,25-(OH)2D3 in comparison to VDREs located at −3.5 and −5.5 kb which do not appear to contribute substantially to vitamin D mediated transcriptional regulation in the intestine.[101] Mechanism wise, TRPV6 transcription is initiated in response to vitamin D Receptor (VDR)-mediated signaling, although other non-direct mechanisms cannot be ruled out.[100][102] Important steps in vitamin D mediated transcriptional regulation include 1) binding of vitamin D on its cognate vitamin D receptor (VDR), 2) the translocation of vitamin D receptor (VDR)-retinoid X receptor heterodimer complex in the nucleus, 3) binding VDR-RXR complex on the TRPV6 gene promoter, 4) recruitment of steroid receptor coactivator 1 and RNA polymerase II on the promoter, and 5) transcriptional activation mediated through histone H4 acetylation events.[103]

Diet

The level of Ca2+ and vitamin D in the diet are the most important regulators of TRPV6 expression.[100] The expression of TRPV6 is thought to be modulated strongly to fine-tune Ca2+ absorption from the diet, especially under conditions when dietary Ca2+ availability is low.[99][100] In rodents, restricting Ca2+ availability in the diet induces dramatic up-regulation in the duodenal expression of TRPV6.[99][100] Calcium influx from the diet and its subsequent binding to calbindin-D9k could be the rate-limiting step that modulates vitamin D-dependent regulation TRPV6.[104] When dietary Ca2+ is insufficient, normal blood calcium levels in TRPV6 KO mice are maintained at the expense of bone.[64][65] In many rodent lines, genetic variations in TRPV6, calbindin-D9k, PMCA1b mRNA influence intestinal Ca absorption and its impact on bone marrow density.[105]

Pregnancy and lactation

Duodenal expression of TRPV6 transcripts is upregulated in WT and VDR KO mice during pregnancy and lactation.[106] The hormone prolactin upregulates TRPV6 transcription and facilitates an increase in intestinal Ca2+ absorption in lactating and pregnant rats, possibly as an adaptive mechanism for overcoming the loss in bone mineralization content during lactation.[107]

Aging

The intestinal expression of TRPV6 in mice varies dramatically by age and relative tissue location.[108] The duodenal expression of TRPV6 is undetectable at P1 and increases 6-fold as mice age to P14. Similarly, the expression also varies with age in the jejunum, where TRPV6 levels increases from P1 to P14, become weak at 1-month age and becomes undetectable in older mice.[108] The expression of TRPV6 in older rats (12-months) is at least 50% lower in comparison to younger counterparts (2-months old).[100] In both WT and VDR KO mice, the age-associated decline in intestinal absorption of Ca2+ is accompanied by a decline in duodenal expression of TRPV6.[109]

Sex hormones

Sex hormones play an important role in the regulation of TRPV6. In comparison to male mice, female mice exhibit a 2-fold higher increase in duodenal expression of TRPV6 mRNA following vitamin D treatment.[citation needed] Sex hormone-associated differential regulation of TRPV6 across genders is believed to be correlated to differences in relative risk to osteoporosis in older postmenopausal women which have been reported to have lower TRPV6 and VDR expression in comparison to males.[77]

Estrogen treatment upregulates TRPV6 transcripts by 8-fold in VDR KO mice and by 4-fold in ovariectomized mice.[102] Greater than 50% reduction in TRPV6 mRNA has been observed in estrogen receptor α KO mice.[106] It is believed that estrogen could be differentially regulating Ca2+ absorption in the duodenum by increasing TRPV6 expression through ERα.[110] Anti-progesterone agent RU486 and anti-estrogen agent ICI 182,780 suppress TRPV6 expression in rodents by their respective antagonist action on progesterone and estrogen receptors.[111] Estrogen, progesterone, and dexamethasone are known to upregulate TRPV6 expression in the cerebral cortex and hypothalamus of mice suggesting a potential involvement of TRPV6 in calcium absorption in the brain.[112]

Glucocorticoids

Subcutaneous administration of glucocorticoids dexamethasone induces both renal and intestinal expression of TRPV6 in mice within 24 hours of whereas oral application of prednisolone reduction in TRPV6 which is also accompanied by reduced Ca2+ absorption in duodenum.[113][114] Intestinal regulation of TRPV6 in response to glucocorticoids appears to be VDR-dependent.[113][114] The enzyme serum and glucocorticoid-regulated kinase 1 (SKG1) regulates TRPV6 expression by enhancing phosphatidylinositol-3-phosphate-5-kinase PIKfyve (PIP5K3).[115] This kinase is critical for the generation of secondary messenger PIP2, a known lipid activator of TRPV6.[115]

Notes


References

  1. ↑ 1.0 1.1 1.2 "TRP channels". Annual Review of Biochemistry 76: 387–417. 2007. doi:10.1146/annurev.biochem.75.103004.142819. PMID 17579562. 
  2. ↑ "A unified nomenclature for the superfamily of TRP cation channels". Molecular Cell 9 (2): 229–31. February 2002. doi:10.1016/s1097-2765(02)00448-3. OCLC 1106536919. PMID 11864597. 
  3. ↑ 3.0 3.1 "CaT1 manifests the pore properties of the calcium-release-activated calcium channel". Nature 410 (6829): 705–9. April 2001. doi:10.1038/35070596. PMID 11287959. Bibcode: 2001Natur.410..705Y. 
  4. ↑ 4.0 4.1 4.2 4.3 4.4 "Structure and function of the calcium-selective TRP channel TRPV6". The Journal of Physiology 599 (10): 2673–2697. February 2020. doi:10.1113/JP279024. PMID 32073143. 
  5. ↑ 5.0 5.1 5.2 5.3 "TRPV5 and TRPV6 Calcium-Selective Channels.". Calcium Entry Channels in Non-Excitable Cells. Methods in signal transduction series. Boca Raton, FL: CRC Press/Taylor & Francis. 2018. pp. 241–274. doi:10.1201/9781315152592-13. ISBN 978-1-315-15259-2. https://www.ncbi.nlm.nih.gov/books/NBK531440/. 
  6. ↑ 6.0 6.1 6.2 6.3 "Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption". The Journal of Biological Chemistry 274 (32): 22739–46. August 1999. doi:10.1074/jbc.274.32.22739. PMID 10428857. 
  7. ↑ 7.0 7.1 "Human calcium transport protein CaT1". Biochemical and Biophysical Research Communications 278 (2): 326–32. November 2000. doi:10.1006/bbrc.2000.3716. PMID 11097838. 
  8. ↑ 8.0 8.1 8.2 "Gene structure and regulation of the murine epithelial calcium channels ECaC1 and 2". Biochemical and Biophysical Research Communications 289 (5): 1287–94. December 2001. doi:10.1006/bbrc.2001.6121. PMID 11741335. 
  9. ↑ 9.0 9.1 9.2 "Function and expression of the epithelial Ca(2+) channel family: comparison of mammalian ECaC1 and 2". The Journal of Physiology 537 (Pt 3): 747–61. December 2001. doi:10.1113/jphysiol.2001.012917. PMID 11744752. 
  10. ↑ 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 "Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer". The Journal of Biological Chemistry 276 (22): 19461–8. June 2001. doi:10.1074/jbc.m009895200. PMID 11278579. 
  11. ↑ "International Union of Pharmacology. XLIX. Nomenclature and structure-function relationships of transient receptor potential channels". Pharmacological Reviews 57 (4): 427–50. December 2005. doi:10.1124/pr.57.4.6. PMID 16382100. 
  12. ↑ 12.0 12.1 "Gene structure and chromosomal mapping of human epithelial calcium channel". Biochemical and Biophysical Research Communications 275 (1): 47–52. August 2000. doi:10.1006/bbrc.2000.3227. PMID 10944439. 
  13. ↑ 13.0 13.1 13.2 "TRPV6 Channels". Mammalian Transient Receptor Potential (TRP) Cation Channels. Handbook of Experimental Pharmacology. 222. Berlin, Heidelberg: Springer Berlin Heidelberg. 2014. pp. 359–84. doi:10.1007/978-3-642-54215-2_14. ISBN 978-3-642-54214-5. 
  14. ↑ 14.0 14.1 "The in vivo TRPV6 protein starts at a non-AUG triplet, decoded as methionine, upstream of canonical initiation at AUG". The Journal of Biological Chemistry 288 (23): 16629–44. June 2013. doi:10.1074/jbc.M113.469726. PMID 23612980. 
  15. ↑ 15.0 15.1 15.2 "Evolutionary analyses reveal independent origins of gene repertoires and structural motifs associated to fast inactivation in calcium-selective TRPV channels". Scientific Reports 10 (1): 8684. May 2020. doi:10.1038/s41598-020-65679-6. PMID 32457384. Bibcode: 2020NatSR..10.8684F. 
  16. ↑ 16.0 16.1 16.2 16.3 16.4 16.5 "TRPV6 exhibits unusual patterns of polymorphism and divergence in worldwide populations". Human Molecular Genetics 15 (13): 2106–13. July 2006. doi:10.1093/hmg/ddl134. PMID 16717058. 
  17. ↑ 17.0 17.1 17.2 "Sequence analysis of human TRPV6 suggests positive selection outside Africa". Biochemical Genetics 47 (1–2): 147–53. February 2009. doi:10.1007/s10528-009-9222-x. PMID 19169858. 
  18. ↑ 18.0 18.1 18.2 18.3 18.4 "TRPV5 and TRPV6 in Transcellular Ca2+ Transport: Regulation, Gene Duplication, and Polymorphisms in African Populations". Transient Receptor Potential Channels. Advances in Experimental Medicine and Biology. 704. 2011. pp. 239–75. doi:10.1007/978-94-007-0265-3_14. ISBN 978-94-007-0264-6. 
  19. ↑ 19.0 19.1 19.2 19.3 "Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies". Laboratory Investigation; A Journal of Technical Methods and Pathology 82 (12): 1755–64. December 2002. doi:10.1097/01.lab.0000043910.41414.e7. PMID 12480925. 
  20. ↑ 20.0 20.1 "TRPV6 protein expression summary". The Human Protein Atlas. https://www.proteinatlas.org/ENSG00000165125-TRPV6. 
  21. ↑ 21.0 21.1 "The role of the TRPV6 channel in cancer". The Journal of Physiology 590 (6): 1369–76. March 2012. doi:10.1113/jphysiol.2011.225862. PMID 22331416. 
  22. ↑ "The TRPV6 gene, cDNA and protein". Cell Calcium 33 (5–6): 509–18. May 2003. doi:10.1016/s0143-4160(03)00066-6. PMID 12765696. 
  23. ↑ "Localization and regulation of the epithelial Ca2+ channel TRPV6 in the kidney". Journal of the American Society of Nephrology 14 (11): 2731–40. November 2003. doi:10.1097/01.asn.0000094081.78893.e8. PMID 14569082. 
  24. ↑ 24.0 24.1 24.2 24.3 24.4 "TRPV6 as A Target for Cancer Therapy". Journal of Cancer 11 (2): 374–387. 2020. doi:10.7150/jca.31640. PMID 31897233. 
  25. ↑ 25.0 25.1 "Knockout of TRPV6 causes osteopenia in mice by increasing osteoclastic differentiation and activity". Cellular Physiology and Biochemistry 33 (3): 796–809. 2014. doi:10.1159/000358653. PMID 24686448. 
  26. ↑ "The transient receptor potential channel TRPV6 is dynamically expressed in bone cells but is not crucial for bone mineralization in mice". Journal of Cellular Physiology 227 (5): 1951–9. May 2012. doi:10.1002/jcp.22923. PMID 21732366. 
  27. ↑ "The transient receptor potential ion channel TRPV6 is expressed at low levels in osteoblasts and has little role in osteoblast calcium uptake". PLOS ONE 6 (11): e28166. 2011-11-29. doi:10.1371/journal.pone.0028166. PMID 22163264. Bibcode: 2011PLoSO...628166L. 
  28. ↑ 28.00 28.01 28.02 28.03 28.04 28.05 28.06 28.07 28.08 28.09 28.10 28.11 28.12 28.13 "Crystal structure of the epithelial calcium channel TRPV6". Nature 534 (7608): 506–11. June 2016. doi:10.1038/nature17975. PMID 27296226. Bibcode: 2016Natur.534..506S. 
  29. ↑ "Swapping of transmembrane domains in the epithelial calcium channel TRPV6". Scientific Reports 7 (1): 10669. September 2017. doi:10.1038/s41598-017-10993-9. PMID 28878326. Bibcode: 2017NatSR...710669S. 
  30. ↑ 30.0 30.1 "The beta-glucuronidase klotho exclusively activates the epithelial Ca2+ channels TRPV5 and TRPV6". Nephrology, Dialysis, Transplantation 23 (11): 3397–402. November 2008. doi:10.1093/ndt/gfn291. PMID 18495742. 
  31. ↑ 31.0 31.1 31.2 "Permeation and selectivity of TRP channels". Annual Review of Physiology 68 (1): 685–717. January 2006. doi:10.1146/annurev.physiol.68.040204.101406. PMID 16460288. 
  32. ↑ 32.0 32.1 32.2 "Outer pore architecture of a Ca2+-selective TRP channel". The Journal of Biological Chemistry 279 (15): 15223–30. April 2004. doi:10.1074/jbc.m312076200. PMID 14736889. 
  33. ↑ "Mg2+-dependent gating and strong inward rectification of the cation channel TRPV6". The Journal of General Physiology 121 (3): 245–60. March 2003. doi:10.1085/jgp.20028752. PMID 12601087. 
  34. ↑ "Heavy metal cations permeate the TRPV6 epithelial cation channel". Cell Calcium 49 (1): 43–55. January 2011. doi:10.1016/j.ceca.2010.11.007. PMID 21146870. 
  35. ↑ 35.0 35.1 35.2 35.3 35.4 "Swapping of transmembrane domains in the epithelial calcium channel TRPV6". Scientific Reports 7 (1): 10669. September 2017. doi:10.1038/s41598-017-10993-9. PMID 28878326. Bibcode: 2017NatSR...710669S. 
  36. ↑ 36.0 36.1 36.2 36.3 "Interplay between calmodulin and phosphatidylinositol 4,5-bisphosphate in Ca2+-induced inactivation of transient receptor potential vanilloid 6 channels". The Journal of Biological Chemistry 288 (8): 5278–90. February 2013. doi:10.1074/jbc.M112.409482. PMID 23300090. 
  37. ↑ 37.0 37.1 37.2 "Ca2+ dependence of the Ca2+-selective TRPV6 channel". The Journal of Biological Chemistry 279 (35): 36546–52. August 2004. doi:10.1074/jbc.m404679200. PMID 15184369. 
  38. ↑ 38.0 38.1 "Regulation of the mouse epithelial Ca2(+) channel TRPV6 by the Ca(2+)-sensor calmodulin". The Journal of Biological Chemistry 279 (28): 28855–61. July 2004. doi:10.1074/jbc.m313637200. PMID 15123711. 
  39. ↑ 39.0 39.1 39.2 "Intracellular ATP supports TRPV6 activity via lipid kinases and the generation of PtdIns(4,5) P₂". FASEB Journal 25 (11): 3915–28. November 2011. doi:10.1096/fj.11-184630. PMID 21810903. 
  40. ↑ 40.0 40.1 40.2 "Phospholipase C-mediated regulation of transient receptor potential vanilloid 6 channels: implications in active intestinal Ca2+ transport". Molecular Pharmacology 75 (3): 608–16. March 2009. doi:10.1124/mol.108.052449. PMID 19073818. 
  41. ↑ "Dynamic but not constitutive association of calmodulin with rat TRPV6 channels enables fine tuning of Ca2+-dependent inactivation". The Journal of Physiology 577 (Pt 1): 31–44. November 2006. doi:10.1113/jphysiol.2006.118661. PMID 16959851. 
  42. ↑ "Competitive regulation of CaT-like-mediated Ca2+ entry by protein kinase C and calmodulin". Proceedings of the National Academy of Sciences of the United States of America 98 (6): 3600–5. March 2001. doi:10.1073/pnas.051511398. PMID 11248124. Bibcode: 2001PNAS...98.3600N. 
  43. ↑ "TRIP Database: a manually curated database of protein-protein interactions for mammalian TRP channels". Nucleic Acids Research 39 (Database issue): D356-61. January 2011. doi:10.1093/nar/gkq814. PMID 20851834. 
  44. ↑ 44.0 44.1 "Mechanisms and regulation of epithelial Ca2+ absorption in health and disease". Annual Review of Physiology 70 (1): 257–71. March 2008. doi:10.1146/annurev.physiol.69.031905.161003. PMID 17850211. 
  45. ↑ 45.0 45.1 45.2 45.3 45.4 45.5 "Calcium channel TRPV6 is involved in murine maternal-fetal calcium transport". Journal of Bone and Mineral Research 23 (8): 1249–56. August 2008. doi:10.1359/jbmr.080314. PMID 18348695. 
  46. ↑ 46.0 46.1 "TRPV6 is a Ca2+ entry channel essential for Ca2+-induced differentiation of human keratinocytes". The Journal of Biological Chemistry 282 (31): 22582–91. August 2007. doi:10.1074/jbc.m611398200. PMID 17550901. 
  47. ↑ 47.0 47.1 47.2 "Expression of epithelial calcium transport system in rat cochlea and vestibular labyrinth". BMC Physiology 10 (1): 1. January 2010. doi:10.1186/1472-6793-10-1. PMID 20113508. 
  48. ↑ 48.0 48.1 48.2 "Vitamin D upregulates expression of ECaC1 mRNA in semicircular canal". Biochemical and Biophysical Research Communications 331 (4): 1353–7. June 2005. doi:10.1016/j.bbrc.2005.04.053. PMID 15883024. 
  49. ↑ 49.0 49.1 49.2 49.3 49.4 "Male fertility depends on Ca²+ absorption by TRPV6 in epididymal epithelia". Science Signaling 4 (171): ra27. May 2011. doi:10.1126/scisignal.2001791. PMID 21540454. 
  50. ↑ 50.0 50.1 50.2 "Excision of Trpv6 gene leads to severe defects in epididymal Ca2+ absorption and male fertility much like single D541A pore mutation". The Journal of Biological Chemistry 287 (22): 17930–41. May 2012. doi:10.1074/jbc.m111.328286. PMID 22427671. 
  51. ↑ 51.0 51.1 51.2 "Molecular aspects of intestinal calcium absorption". World Journal of Gastroenterology 21 (23): 7142–54. June 2015. doi:10.3748/wjg.v21.i23.7142. PMID 26109800. 
  52. ↑ 52.0 52.1 52.2 52.3 "Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene". Journal of Bone and Mineral Research 22 (2): 274–85. February 2007. doi:10.1359/jbmr.061110. PMID 17129178. 
  53. ↑ "Evaluation and Comparison of Vitamin D Responsive Gene Expression in Ovine, Canine and Equine Kidney". PLOS ONE 11 (9): e0162598. 2016-09-15. doi:10.1371/journal.pone.0162598. PMID 27632366. Bibcode: 2016PLoSO..1162598A. 
  54. ↑ "Placental transfer of inorganic ions and water". Physiological Reviews 77 (3): 805–36. July 1997. doi:10.1152/physrev.1997.77.3.805. PMID 9234966. 
  55. ↑ "Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation". Endocrine Reviews 18 (6): 832–72. December 1997. doi:10.1210/edrv.18.6.0319. PMID 9408745. 
  56. ↑ "Intrauterine Growth Restriction: Antenatal and Postnatal Aspects". Clinical Medicine Insights. Pediatrics 10: 67–83. January 2016. doi:10.4137/cmped.s40070. PMID 27441006. 
  57. ↑ 57.0 57.1 "Diverse calcium channel types are present in the human placental syncytiotrophoblast basal membrane". Placenta 27 (11–12): 1082–95. November 2006. doi:10.1016/j.placenta.2005.12.007. PMID 16564089. 
  58. ↑ "Uterine TRPV6 expression during the estrous cycle and pregnancy in a mouse model". American Journal of Physiology. Endocrinology and Metabolism 293 (1): E132-8. July 2007. doi:10.1152/ajpendo.00666.2006. PMID 17374692. 
  59. ↑ "Expression of calcium channels along the differentiation of cultured trophoblast cells from human term placenta". Biology of Reproduction 67 (5): 1473–9. November 2002. doi:10.1095/biolreprod.102.005397. PMID 12390878. 
  60. ↑ "Differential expression of calcium transport channels in placenta primary cells and tissues derived from preeclamptic placenta". Molecular and Cellular Endocrinology 367 (1–2): 21–30. March 2013. doi:10.1016/j.mce.2012.12.012. PMID 23267838. 
  61. ↑ "Fluid shear triggers microvilli formation via mechanosensitive activation of TRPV6". Nature Communications 6 (1): 8871. November 2015. doi:10.1038/ncomms9871. PMID 26563429. Bibcode: 2015NatCo...6.8871M. 
  62. ↑ "The development of signal transduction pathways during epididymal maturation is calcium dependent". Developmental Biology 268 (1): 53–63. April 2004. doi:10.1016/j.ydbio.2003.12.015. PMID 15031104. https://ro.uow.edu.au/scipapers/938. 
  63. ↑ "Coupling of TRPV6 and TMEM16A in epithelial principal cells of the rat epididymis". The Journal of General Physiology 148 (2): 161–82. August 2016. doi:10.1085/jgp.201611626. PMID 27481714. 
  64. ↑ 64.0 64.1 64.2 64.3 "Trpv6 mediates intestinal calcium absorption during calcium restriction and contributes to bone homeostasis". Bone 47 (2): 301–8. August 2010. doi:10.1016/j.bone.2010.04.595. PMID 20399919. 
  65. ↑ 65.0 65.1 65.2 "The Involvement of TRP Channels in Bone Homeostasis". Frontiers in Endocrinology 3: 99. 2012. doi:10.3389/fendo.2012.00099. PMID 22934090. 
  66. ↑ "Role of the calcium-sensing receptor in calcium regulation of epidermal differentiation and function". Best Practice & Research. Clinical Endocrinology & Metabolism 27 (3): 415–27. June 2013. doi:10.1016/j.beem.2013.03.002. PMID 23856269. 
  67. ↑ 67.0 67.1 67.2 67.3 "Lack of pendrin HCO3- transport elevates vestibular endolymphatic [Ca2+ by inhibition of acid-sensitive TRPV5 and TRPV6 channels"]. American Journal of Physiology. Renal Physiology 292 (5): F1314-21. May 2007. doi:10.1152/ajprenal.00432.2006. PMID 17200157. 
  68. ↑ 68.0 68.1 "Functional expression of transient receptor potential channels in human endometrial stromal cells during the luteal phase of the menstrual cycle". Human Reproduction 30 (6): 1421–36. June 2015. doi:10.1093/humrep/dev068. PMID 25820697. 
  69. ↑ 69.0 69.1 69.2 "Coexpression and estrogen-mediated regulation of TRPV6 and PMCA1 in the human endometrium during the menstrual cycle". Molecular Reproduction and Development 78 (4): 274–82. April 2011. doi:10.1002/mrd.21303. PMID 21400627. 
  70. ↑ 70.0 70.1 "The functional expression of transient receptor potential channels in the mouse endometrium". Human Reproduction 32 (3): 615–630. March 2017. doi:10.1093/humrep/dew344. PMID 28077439. 
  71. ↑ "TRPV6 Variants Interfere with Maternal-Fetal Calcium Transport through the Placenta and Cause Transient Neonatal Hyperparathyroidism". American Journal of Human Genetics 102 (6): 1104–1114. June 2018. doi:10.1016/j.ajhg.2018.04.006. PMID 29861107. 
  72. ↑ "TRPV6 Gene Mutation in a Dizygous Twin With Transient Neonatal Hyperparathyroidism". Journal of the Endocrine Society 3 (3): 602–606. March 2019. doi:10.1210/js.2018-00374. PMID 30820485. 
  73. ↑ "TRPV6 compound heterozygous variants result in impaired placental calcium transport and severe undermineralization and dysplasia of the fetal skeleton". American Journal of Medical Genetics. Part A 176 (9): 1950–1955. September 2018. doi:10.1002/ajmg.a.40484. PMID 30144375. 
  74. ↑ 74.0 74.1 "TRPV6 variants confer susceptibility to chronic pancreatitis in the Chinese population". Human Mutation 41 (8): 1351–1357. August 2020. doi:10.1002/humu.24032. PMID 32383311. 
  75. ↑ 75.0 75.1 75.2 75.3 "Variants That Affect Function of Calcium Channel TRPV6 Are Associated With Early-Onset Chronic Pancreatitis". Gastroenterology 158 (6): 1626–1641.e8. May 2020. doi:10.1053/j.gastro.2020.01.005. PMID 31930989. 
  76. ↑ 76.0 76.1 Suzuki, Yoshiro Pasch, Andreas Bonny, Olivier Mohaupt, Markus G. Hediger, Matthias A. Frey, Felix J. (2017-08-02). Gain-of-function haplotype in the epithelial calcium channel TRPV6 is a risk factor for renal calcium stone formation. 17. 1613–8. doi:10.1093/hmg/ddn048. OCLC 1156692319. 
  77. ↑ 77.0 77.1 "Calcium channel TRPV6 expression in human duodenum: different relationships to the vitamin D system and aging in men and women". Journal of Bone and Mineral Research 21 (11): 1770–7. November 2006. doi:10.1359/jbmr.060721. PMID 17002582. 
  78. ↑ 78.0 78.1 "Activation of the transient receptor potential cation channel TRPC6 is required for chondrocyte phenotypic stability". Osteoarthritis and Cartilage 24: S152–S153. April 2016. doi:10.1016/j.joca.2016.01.298. ISSN 1063-4584. 
  79. ↑ 79.0 79.1 79.2 79.3 "Integration of human and mouse genetics reveals pendrin function in hearing and deafness". Cellular Physiology and Biochemistry 28 (3): 535–44. 2011. doi:10.1159/000335163. PMID 22116368. 
  80. ↑ "TRPV6 is a prognostic marker in early-stage cervical squamous cell carcinoma". Tumour Biology 37 (12): 15743–15751. October 2016. doi:10.1007/s13277-016-5368-4. PMID 27747588. 
  81. ↑ 81.0 81.1 "Expression and prognostic roles of TRPV5 and TRPV6 in non-small cell lung cancer after curative resection". Asian Pacific Journal of Cancer Prevention 15 (6): 2559–63. 2014-03-30. doi:10.7314/apjcp.2014.15.6.2559. PMID 24761864. 
  82. ↑ "Decreased expression of the epithelial Ca2+ channel TRPV5 and TRPV6 in human renal cell carcinoma associated with vitamin D receptor". The Journal of Urology 186 (6): 2419–25. December 2011. doi:10.1016/j.juro.2011.07.086. PMID 22019165. 
  83. ↑ 83.0 83.1 83.2 83.3 83.4 "CaT1 expression correlates with tumor grade in prostate cancer". Biochemical and Biophysical Research Communications 282 (3): 729–34. April 2001. doi:10.1006/bbrc.2001.4638. PMID 11401523. 
  84. ↑ 84.0 84.1 "Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression". Oncogene 22 (49): 7858–61. October 2003. doi:10.1038/sj.onc.1206895. PMID 14586412. 
  85. ↑ "High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters". Cellular Physiology and Biochemistry 28 (5): 813–22. 2011. doi:10.1159/000335795. PMID 22178934. 
  86. ↑ 86.0 86.1 "The role of TRPV6 in breast carcinogenesis". Molecular Cancer Therapeutics 7 (2): 271–9. February 2008. doi:10.1158/1535-7163.mct-07-0478. PMID 18245667. 
  87. ↑ "Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer". Molecular Cancer Therapeutics 11 (10): 2158–68. October 2012. doi:10.1158/1535-7163.mct-11-0965. PMID 22807578. 
  88. ↑ 88.0 88.1 88.2 "TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways". Oncogene 26 (52): 7380–5. November 2007. doi:10.1038/sj.onc.1210545. PMID 17533368. 
  89. ↑ "TRPV6 determines the effect of vitamin D3 on prostate cancer cell growth". PLOS ONE 6 (2): e16856. February 2011. doi:10.1371/journal.pone.0016856. PMID 21347289. Bibcode: 2011PLoSO...616856L. 
  90. ↑ "Tamoxifen inhibits TRPV6 activity via estrogen receptor-independent pathways in TRPV6-expressing MCF-7 breast cancer cells". Molecular Cancer Research 7 (12): 2000–10. December 2009. doi:10.1158/1541-7786.mcr-09-0188. PMID 19996302. 
  91. ↑ "Suppression of aberrant transient receptor potential cation channel, subfamily V, member 6 expression in hyperproliferative colonic crypts by dietary calcium". American Journal of Physiology. Gastrointestinal and Liver Physiology 299 (3): G593-601. September 2010. doi:10.1152/ajpgi.00193.2010. PMID 20508153. 
  92. ↑ "Mutations in calmodulin-binding domains of TRPV4/6 channels confer invasive properties to colon adenocarcinoma cells". Channels 14 (1): 101–109. December 2020. doi:10.1080/19336950.2020.1740506. PMID 32186440. 
  93. ↑ "3 enhances TRPV6 transcription through p38 MAPK activation and GADD45 expression". The Journal of Steroid Biochemistry and Molecular Biology 172: 55–61. September 2017. doi:10.1016/j.jsbmb.2017.05.013. PMID 28578001. 
  94. ↑ "Calcium deficiency-induced and TRP channel-regulated IGF1R-PI3K-Akt signaling regulates abnormal epithelial cell proliferation". Cell Death and Differentiation 21 (4): 568–81. April 2014. doi:10.1038/cdd.2013.177. PMID 24336047. 
  95. ↑ "TRPV6 modulates proliferation of human pancreatic neuroendocrine BON-1 tumour cells". Bioscience Reports 36 (4). August 2016. doi:10.1042/bsr20160106. PMID 27450545. 
  96. ↑ "Expression and prognostic significance of TRPV6 in the development and progression of pancreatic cancer". Oncology Reports 39 (3): 1432–1440. March 2018. doi:10.3892/or.2018.6216. PMID 29344675. 
  97. ↑ "TRPV6 mediates capsaicin-induced apoptosis in gastric cancer cells--Mechanisms behind a possible new "hot" cancer treatment". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1773 (4): 565–76. April 2007. doi:10.1016/j.bbamcr.2007.01.001. PMID 17292493. 
  98. ↑ "TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma". Diagnostic Pathology 11 (1): 14. January 2016. doi:10.1186/s13000-016-0457-7. PMID 26818094. 
  99. ↑ 99.0 99.1 99.2 "Calcium transporter 1 and epithelial calcium channel messenger ribonucleic acid are differentially regulated by 1,25 dihydroxyvitamin D3 in the intestine and kidney of mice". Endocrinology 144 (9): 3885–94. September 2003. doi:10.1210/en.2003-0314. PMID 12933662. 
  100. ↑ 100.0 100.1 100.2 100.3 100.4 100.5 "Effect of age, vitamin D, and calcium on the regulation of rat intestinal epithelial calcium channels". Archives of Biochemistry and Biophysics 437 (1): 51–8. May 2005. doi:10.1016/j.abb.2005.02.007. PMID 15820216. 
  101. ↑ 101.0 101.1 "The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells". Molecular Endocrinology 20 (6): 1447–61. June 2006. doi:10.1210/me.2006-0031. PMID 16574738. 
  102. ↑ 102.0 102.1 "Vitamin D receptor (VDR) knockout mice reveal VDR-independent regulation of intestinal calcium absorption and ECaC2 and calbindin D9k mRNA". The Journal of Nutrition 133 (2): 374–80. February 2003. doi:10.1093/jn/133.2.374. PMID 12566470. 
  103. ↑ "Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects". Physiological Reviews 96 (1): 365–408. January 2016. doi:10.1152/physrev.00014.2015. PMID 26681795. 
  104. ↑ "Intestinal calcium absorption: Molecular vitamin D mediated mechanisms". Journal of Cellular Biochemistry 88 (2): 332–9. February 2003. doi:10.1002/jcb.10360. PMID 12520535. 
  105. ↑ "Gene-by-diet interactions influence calcium absorption and bone density in mice". Journal of Bone and Mineral Research 29 (3): 657–65. March 2014. doi:10.1002/jbmr.2065. PMID 23955923. 
  106. ↑ 106.0 106.1 "Intestinal calcium transporter genes are upregulated by estrogens and the reproductive cycle through vitamin D receptor-independent mechanisms". Journal of Bone and Mineral Research 18 (10): 1725–36. October 2003. doi:10.1359/jbmr.2003.18.10.1725. PMID 14584880. 
  107. ↑ "Two-step stimulation of intestinal Ca(2+) absorption during lactation by long-term prolactin exposure and suckling-induced prolactin surge". American Journal of Physiology. Endocrinology and Metabolism 297 (3): E609-19. September 2009. doi:10.1152/ajpendo.00347.2009. PMID 19567804. 
  108. ↑ 108.0 108.1 "v1.3 Mediate Distal Small Intestine Calcium Absorption Before Weaning". Cellular and Molecular Gastroenterology and Hepatology 8 (4): 625–642. 2019. doi:10.1016/j.jcmgh.2019.07.005. PMID 31398491. 
  109. ↑ "Age-dependent alterations in Ca2+ homeostasis: role of TRPV5 and TRPV6". American Journal of Physiology. Renal Physiology 291 (6): F1177-83. December 2006. doi:10.1152/ajprenal.00038.2006. PMID 16705151. 
  110. ↑ "Estrogen Regulates Duodenal Calcium Absorption Through Differential Role of Estrogen Receptor on Calcium Transport Proteins". Digestive Diseases and Sciences 65 (12): 3502–3513. January 2020. doi:10.1007/s10620-020-06076-x. PMID 31974908. 
  111. ↑ "Uterine and placental expression of TRPV6 gene is regulated via progesterone receptor- or estrogen receptor-mediated pathways during pregnancy in rodents". Reproductive Biology and Endocrinology 7 (1): 49. May 2009. doi:10.1186/1477-7827-7-49. PMID 19457270. 
  112. ↑ Park, Seon-Young; Yoo, Yeong-Min; Jung, Eui-Man; Jeung, Eui-Bae (April 2020). "The effect of steroid hormone on the expression of the calcium-processing proteins in the immature female rat brain". Journal of Chemical Neuroanatomy 105: 101767. doi:10.1016/j.jchemneu.2020.101767. PMID 32061997. 
  113. ↑ 113.0 113.1 "The negative effect of dexamethasone on calcium-processing gene expressions is associated with a glucocorticoid-induced calcium-absorbing disorder". Life Sciences 85 (3–4): 146–52. July 2009. doi:10.1016/j.lfs.2009.05.013. PMID 19490920. 
  114. ↑ 114.0 114.1 "Expression of Calcium Transport Genes in the Placenta of Calbindin-D9k and -D28k Knockout Mice.". Biology of Reproduction 85 (Suppl_1): 449. 2011-07-01. doi:10.1093/biolreprod/85.s1.449. ISSN 0006-3363. 
  115. ↑ 115.0 115.1 "Regulation of the Ca(2+) channel TRPV6 by the kinases SGK1, PKB/Akt, and PIKfyve". The Journal of Membrane Biology 233 (1–3): 35–41. February 2010. doi:10.1007/s00232-009-9222-0. PMID 20041238. 

Further reading

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:TRPV6&oldid=3627071"